[go: up one dir, main page]

NO20092609L - Tannate salt of rasagiline - Google Patents

Tannate salt of rasagiline

Info

Publication number
NO20092609L
NO20092609L NO20092609A NO20092609A NO20092609L NO 20092609 L NO20092609 L NO 20092609L NO 20092609 A NO20092609 A NO 20092609A NO 20092609 A NO20092609 A NO 20092609A NO 20092609 L NO20092609 L NO 20092609L
Authority
NO
Norway
Prior art keywords
rasagiline
tannate salt
tannate
salt
rasagilin
Prior art date
Application number
NO20092609A
Other languages
English (en)
Inventor
Tamas Koltai
Anton Frenkel
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20092609L publication Critical patent/NO20092609L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer rasagilintannat, sammensetninger og en fremgangsmåte for fremstilling derav.
NO20092609A 2006-12-14 2009-07-08 Tannate salt of rasagiline NO20092609L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87503806P 2006-12-14 2006-12-14
PCT/US2007/025516 WO2008076315A1 (en) 2006-12-14 2007-12-13 Tannate salt of rasagiline

Publications (1)

Publication Number Publication Date
NO20092609L true NO20092609L (no) 2009-09-04

Family

ID=39536617

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092609A NO20092609L (no) 2006-12-14 2009-07-08 Tannate salt of rasagiline

Country Status (24)

Country Link
US (1) US7547806B2 (no)
EP (1) EP2101570B1 (no)
JP (1) JP5356248B2 (no)
KR (1) KR101077835B1 (no)
CN (1) CN101600346B (no)
AU (1) AU2007334493B2 (no)
BR (1) BRPI0718339A2 (no)
CA (1) CA2672452C (no)
DK (1) DK2101570T3 (no)
EA (1) EA016843B1 (no)
ES (1) ES2420124T3 (no)
HK (1) HK1129277A1 (no)
HR (1) HRP20130396T1 (no)
IL (1) IL198984A (no)
MX (1) MX2009006252A (no)
NO (1) NO20092609L (no)
NZ (1) NZ577623A (no)
PL (1) PL2101570T3 (no)
PT (1) PT2101570E (no)
RS (1) RS52784B (no)
SI (1) SI2101570T1 (no)
UA (1) UA97382C2 (no)
WO (1) WO2008076315A1 (no)
ZA (1) ZA200903904B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008507586A (ja) * 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
ES2371883T3 (es) * 2004-11-24 2012-01-11 Teva Pharmaceutical Industries Ltd. Composiciones de rasagilina de disgregación oral.
PL1848415T3 (pl) * 2005-02-17 2013-10-31 Teva Pharma Terapia kombinowana obejmująca octan glatirameru oraz rasagilinę do leczenia stwardnienia rozsianego
EP1848402B2 (en) * 2005-02-23 2019-02-20 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2643235C (en) * 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) * 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
ZA200903904B (en) 2006-12-14 2010-08-25 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
AU2008296908B2 (en) * 2007-09-05 2014-01-09 Teva Pharmaceutical Industries, Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
WO2009151625A1 (en) * 2008-06-13 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline for parkinson's disease modification
WO2009154782A1 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
US7968749B2 (en) 2008-06-19 2011-06-28 Teva Pharmaceutical Industries, Ltd. Process for preparing and drying solid rasagiline base
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
EP2218444A3 (en) 2009-01-23 2010-08-25 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline formulation
DK2451771T3 (da) 2009-07-09 2014-09-08 Ratiopharm Gmbh Salte af rasagilin og farmaceutiske fremstillingsmåder heraf
EP2325159A1 (en) 2009-11-24 2011-05-25 LEK Pharmaceuticals d.d. Novel salts of rasagiline
CA2785501A1 (en) * 2009-12-22 2011-07-21 Teva Pharmaceutical Industries Ltd. 3-keto-n-propargyl-1-aminoindan
US20120269871A1 (en) 2009-12-30 2012-10-25 Actavis Group Ptc Ehf Solid state forms of rasagiline salts
WO2011095985A2 (en) * 2010-02-02 2011-08-11 Glenmark Generics Limited Rasagiline salts and processes for the preparation thereof
EP2603212A4 (en) 2010-07-27 2014-01-08 Teva Pharma USE OF RASAGILINE FOR THE TREATMENT OF SMOKING DISORDER
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
BR112014008555A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-formil-propargil-aminoindano
EA201491734A1 (ru) 2012-03-21 2015-01-30 Синтон Бв Стабилизированные фармацевтические композиции, содержащие соли разагилина
EP2884972A4 (en) 2012-08-17 2016-05-11 Teva Pharma PARENTERAL FORMULATION OF RASAGILINE
RU2696588C2 (ru) * 2014-04-17 2019-08-05 Мерк Шарп И Доум Корп. Комплекс танната ситаглиптина
CN107125438A (zh) * 2016-02-29 2017-09-05 湖南晶天科技实业有限公司 一种饲料添加剂鞣酸生物碱及其制备方法以及一种复合添加剂和一种饲料
TW201818969A (zh) * 2016-10-19 2018-06-01 日商帝化製藥股份有限公司 在生體內之藥物溶出控制用組成物

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en) 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) * 1996-06-28 1997-09-02 Jame Fine Chemicals, Inc. Process for preparing antihistamine tannates
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
PT966435E (pt) 1996-12-18 2005-06-30 Yissum Res Dev Co Derivados aminoindano
GB9715082D0 (en) * 1997-07-17 1997-09-24 Scherer Ltd R P Treatment of attention deficit hyperactivity disorder and narcolepsy
FR2771102B1 (fr) * 1997-11-14 2000-12-15 Biocoral Inc Procede pour induire la differenciation osteoblastique de cellules de tissu adipeux extramedullaire humain
WO2002005745A2 (en) * 2000-07-14 2002-01-24 Cadila Pharmaceuticals Limited The process of manufacturing pharmaceutical grade tannates
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US6869618B2 (en) 2001-04-10 2005-03-22 Kiel Laboratories, Inc. Process for preparing tannate liquid and semi-solid dosage forms
WO2004045515A2 (en) 2002-11-15 2004-06-03 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US20040157784A1 (en) * 2003-02-10 2004-08-12 Jame Fine Chemicals, Inc. Opiod tannate compositions
DE602004017166D1 (de) * 2003-03-25 2008-11-27 Kiel Lab Inc Gabapentintannat in flüssigen und/oder halbfesten dosierformen
ES2335284T3 (es) * 2003-09-03 2010-03-24 Glaxo Group Limited Nuevo procedimiento para preparar derivados de pleuromutilina.
US20050053656A1 (en) * 2003-09-05 2005-03-10 Ping Jeffrey H. Compositions and methods for treating pain
US20050202050A1 (en) * 2004-03-12 2005-09-15 Kiel Jeffrey S. Single tank process for preparing tannate liquid and semi-solid dosage forms
JP2008507586A (ja) 2004-07-26 2008-03-13 テバ ファーマシューティカル インダストリーズ リミティド ラサグリンを含む、医薬投与剤
CA2588293C (en) 2004-11-24 2013-07-02 Teva Pharmaceutical Industries Ltd. Rasagiline orally disintegrating compositions
EP1848402B2 (en) 2005-02-23 2019-02-20 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CN101622225B (zh) 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
CA2643235C (en) 2006-02-21 2014-06-17 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of multiple system atrophy
AU2007235517B2 (en) 2006-04-03 2013-01-31 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Restless Legs Syndrome
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
ZA200903904B (en) 2006-12-14 2010-08-25 Teva Pharma Tannate salt of rasagiline
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff

Also Published As

Publication number Publication date
CN101600346A (zh) 2009-12-09
BRPI0718339A2 (pt) 2014-02-18
JP5356248B2 (ja) 2013-12-04
KR101077835B1 (ko) 2011-10-28
US20080146676A1 (en) 2008-06-19
CN101600346B (zh) 2013-08-21
DK2101570T3 (da) 2013-05-27
AU2007334493B2 (en) 2010-12-02
PT2101570E (pt) 2013-05-17
US7547806B2 (en) 2009-06-16
HK1129277A1 (en) 2009-11-27
HRP20130396T1 (en) 2013-06-30
PL2101570T3 (pl) 2013-07-31
AU2007334493A1 (en) 2008-06-26
ZA200903904B (en) 2010-08-25
IL198984A (en) 2013-03-24
EP2101570A4 (en) 2011-04-06
NZ577623A (en) 2011-05-27
CA2672452A1 (en) 2008-06-26
WO2008076315A1 (en) 2008-06-26
IL198984A0 (en) 2010-02-17
SI2101570T1 (sl) 2013-06-28
UA97382C2 (ru) 2012-02-10
ES2420124T3 (es) 2013-08-22
CA2672452C (en) 2012-07-03
EA016843B1 (ru) 2012-07-30
EA200970580A1 (ru) 2009-12-30
JP2010513280A (ja) 2010-04-30
RS52784B (en) 2013-10-31
MX2009006252A (es) 2009-10-13
KR20090088433A (ko) 2009-08-19
EP2101570A1 (en) 2009-09-23
EP2101570B1 (en) 2013-02-13

Similar Documents

Publication Publication Date Title
NO20092609L (no) Tannate salt of rasagiline
NO20092611L (no) Krystallinsk faststoff Rasagilin base
EA200900781A1 (ru) 4-фенилпиран-3,5-дионы, 4-фенилтиопиран-3,5-дионы и циклогексантрионы, как новые гербициды
NO20083153L (no) Kjemiske forbindelser
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
UA103319C2 (en) Thiazole- and oxazole-benzene sulfonamide compounds
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
DE602006020327D1 (de) 2-phenoxy-n-(1,3,4-thiadizol-2-yl)pyridin-3-aminder-hemmer zur behandlung thromboembolischer erkrankungen
TW200732349A (en) Anti-OX40L antibodies and methods using same
MX2009004813A (es) Derivados de azaadamantano y sus usos como ligandos de receptores de acetilcolina nicotinicos.
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
EA200702529A1 (ru) Фунгицидная комбинация биологически активных веществ
FR2934863B1 (fr) Copolyamide semi-aromatique et son procede de preparation
EA200801199A1 (ru) Ингибиторы киназы
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
NO20083593L (no) Anti-EphrinB2-antistoffer og fremgangsmater for anvendelse av disse
NO20082749L (no) Fremgangsmate for fremstilling av ferri-succinylkasein
EA201170483A1 (ru) Твердая фармацевтическая композиция
MX2009009490A (es) Profarmacos novedosos.
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
WO2008051539A3 (en) Processes for preparing palonosetron salts
EA201000069A1 (ru) Новые гербициды
MX2007011826A (es) Composiciones farmaceuticas de liberacion controlada de liotironina y metodos para elaborar y utilizar las mismas.
TW200638932A (en) CCI-779 polymorph and use thereof
UA96269C2 (uk) Інгібітори цистеїнпротеази та їх терапевтичне застосування

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application